Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

920

Current progress in targeting mitotic kinases in PDAC

Thomas M A Barlow1, Ilse Rooman2, Steven Ballet1

  • 1Research Group of Organic Chemistry, Vrije Universiteit Brussel Pleinlaan 2, Elsene 1050 Brussels Belgium steven.ballet@vub.be.

RSC Medicinal Chemistry
|June 26, 2025
PubMed

Insights

Pancreatic ductal adenocarcinoma (PDAC) mortality is rising due to limited treatments. Targeting mitotic kinases like CDKs and Aurora kinases offers a promising therapeutic strategy for this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) mortality is projected to rise significantly, becoming a leading cause of cancer death.
  • Current therapeutic options for PDAC remain limited, highlighting an urgent need for novel treatment strategies.
  • Advances in targeting KRAS offer new avenues, but broader therapeutic solutions are still required.

Purpose of the Study:

  • To review current efforts and advances in targeting mitotic kinases for PDAC treatment.
  • To discuss the clinical and therapeutic perspectives of targeting specific mitotic kinases, including CDKs, Wee1, Chk1, Plk1, and Aurora kinases.

Main Methods:

  • Literature review of ongoing research in PDAC therapeutics.
  • Analysis of clinical and preclinical data on mitotic kinase inhibitors.
  • Discussion of therapeutic strategies targeting cell division pathways.

Main Results:

  • Mitotic kinase targeting, including CDKs, Wee1, Chk1, Plk1, and Aurora kinases, presents a viable therapeutic avenue for PDAC.
  • Progress has been made in developing drugs targeting these kinases, with ongoing clinical investigations.
  • Specific advances and challenges for each targeted kinase family are presented.

Conclusions:

  • Targeting mitotic kinases represents a critical and evolving strategy to address the unmet therapeutic needs in PDAC.
  • Further research and clinical development are essential to translate these findings into effective PDAC treatments.
  • The reviewed mitotic kinase targets offer potential for improved patient outcomes in pancreatic cancer.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K